FROM THE EDITORIAL BOARD | Glen D. Stettin. MD

obody intends to get addicted to opioids. Sadly, it happens far too often. More sadly, it is easier to get addicted than to get unaddicted.

Americans are 4.8% of the world's inhabitants, yet we consume a highly disproportionate share of many commercially available opioids, including hydrocodone (99.7%), oxycodone (69%), morphine (49.6%), hydromorphone (45%), and fentanyl (29%). We consume more than 5 times as many daily doses as Europeans, and our use has quintupled since the 1990s.

WE HAVE MORE TO DO TO PREVENT AND TREAT OPIOID ADDICTION. WE MUST ELIMINATE UNSAFE OPIOID EXPOSURE AND IMPROVE ACCESS TO TREATMENT.

Americans overconsume opioids for several reasons. Culturally, and I generalize, we believe pain should be treated. We believe drugs are better than nondrug treatments and opioids are better than nonopioids. Our preferences, fueled by marketing budgets of opioid manufacturers, nudged us to seek opioids for pain and our physicians to oblige. Easy access to prescription opioids made getting addicted easy.

There is good news. America's consumption of prescription opioids has been declining since 2012. During this time, pharmacy benefit managers have expanded efforts to accelerate this trend. For example, the CDC's revised opioid prescribing guidelines in 2017 were quickly implemented by Express Scripts to reduce unsafe use of prescription opioids. We focused on making better decisions—fewer and smaller prescriptions; safer dosing, formulations, and combinations—the easiest decisions for physicians,

pharmacists, and patients. We implemented coverage policies to curtail overuse and ensure needed access. We provided patients with education, monitoring, counseling, and safe in-home disposal of unused opioids. As a result, first-time users' average day supply per fill declined by 55%, from 18.6 to 8.3 days, and 93% of first-time fills are now for 7 days or less. And 78% of new users with initial prescriptions for long-acting opioids are redirected to safer, short-acting opioids.

But let us not fool ourselves. We have more to do to prevent and treat opioid addiction.

We must advocate for solutions that eliminate unsafe opioid exposure and improve access to effective addiction treatment. Practices can set defaults and prompts in electronic prescribing systems to increase adherence to prescribing guidelines. Examples include defaulting initial prescriptions to a 3-day supply and prompting physi-

cians to reconsider requests for long-acting opioids in opioid-naïve patients, regimens that exceed dosing guidelines, and unsafe combinations of opioids with benzodiazepines or muscle relaxants. Policy makers can improve prescription drug monitoring programs and require that prescribers use them. For people struggling with addiction, we need safer and more effective ways to help them transition off of opioids completely or onto maintenance therapies. Finally, we need easier access to naloxone for preventing overdose deaths.

Our work in preventing and treating opioid addiction may never be complete, but it will be increasingly successful if we continue to focus on making it harder to get addicted and making it easier to get unaddicted or, at least, easier to get maintenance treatment that restores dignity and function to those who got addicted despite their best intentions.

SEE ALSO THE CENTER FOR BIOSIMILARS*

494

Could Biosimilars of Orphan Drugs Reduce Patients' Cost Burdens?

In recent years, spending on specialty drugs, including spending on a proliferation of orphan drugs that treat rare diseases, has raised concerns about sustainability of the healthcare system. However, a recently released report from IQVIA reported that only 9.6% of annual US drug spending is on orphan indications.

centerforbiosimilars.com/link/37

Mission Statement

The American Journal of Managed Care® is an independent, peer-reviewed forum for the dissemination of research relating to clinical, economic, and policy aspects of financing and delivering healthcare. The journal's mission is to publish original research relevant to clinical decision makers and policy makers as they work to promote the efficient delivery of high-quality care.

Indexing

The American Journal of Managed Care® is included in the following abstracting and indexing sources:

- ▶ Medline/PubMed
- ➤ EMBASE/Excerpta Medica
- > Current Contents/Clinical Medicine
- > Science Citation Index Expanded
- ➤ Current Contents/Social & Behavioral Sciences
- > Social Sciences Citation Index
- > Cumulative Index to Nursing and Allied Health Literature (CINAHL)
- ➤ International Pharmaceutical Abstracts (IPA)
- ➤ Physiotherapy Evidence Database (PEDro)



Opinions expressed by authors, contributors, and advertisers are their own and not necessarily those of Managed Care & Healthcare Communications, LLC, the editorial staff, or any member of the editorial advisory board. Managed Care & Healthcare Communications, LLC, is not responsible for accuracy of dosages given in articles printed herein. The appearance of advertisements in this journal is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. Managed Care & Healthcare Communications, LLC, disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.

The American Journal of Managed Care® ISSN 1088-0224 (print) & ISSN 1936-2692 (online), UPS 0015-973 is published monthly by Managed Care & Healthcare Communications, LLC, 2 Clarke Drive, Suite 100, Cranbury, NJ 08512. Copyright © 2018 by Managed Care & Healthcare Communications, LLC. All rights reserved. As provided by US convright law, no part of this publication may be reproduced, displayed, or transmitted in any form or by any means, electronic or mechanical, without the prior written permission of the publisher. For subscription inquiries or change of address, please call 609-716-7777 or email Jon Severn at circulation@mjhassoc.com. For permission to photocopy or reuse material from this journal, please contact the Copyright Clearance Center, Inc, 222 Rosewood Drive, Danvers, MA 01923; Tel: 978-750-8400; Web: www.copyright.com. Reprints of articles are available in minimum quantities of 250 copies. To order custom reprints, please contact Gilbert Hernandez, The American Journal of Managed Care®, ghernandez@ajmc.com; Tel: 609-716-7777. Periodicals class postage paid at Princeton, NJ, and additional mailing offices. POSTMASTER: Send address changes to: The American Journal of Managed Care®, 2 Clarke Drive, Suite 100. Cranbury, NJ 08512, Subscription rates: US: Individual: \$239: institutional: \$359; Outside the US: Individual: \$359; institutional: \$479. single copies: \$35 each. Payable in US funds. The American Journal of Managed Care® is a registered trademark of Managed Care & Healthcare Communications, LLC. www.ajmc.com • Printed on acid-free paper.

NOVEMBER 2018 www.ajmc.com